The ascent of a healthcare manager professional : John Adlesich

The climb of a public health manager expert : John Adlesich on healthcare industry trends in 2021: Cooperative competition, or coopetition, is a key trend in health care. While some providers view big-box stores, nationwide pharmaceutical chains and other new entrants as threats, other organizations see opportunity. Their strategy is to leverage the capabilities of these power players to lower the cost of care, increase downstream market capture and focus on core specialty services while remaining highly connected to the patient. Offload financially draining services. Organizations like CVS and Walmart now offer basic primary care, simple diagnostic services and chronic disease management — services that health systems have struggled to provide and do so profitably. Identifying opportunities to partner with retail organizations to fill this gap can help simplify organizational services, increase access and provide better patient care at a lower cost.

John Adlesich on behavior therapy in 2021: All behavioral therapies share the same reward/consequence paradigm for changing behavior and learning new skills, and they may include some overlap in the way that they are implemented. Despite these similarities, however, children may respond more fully to one approach over another for any number of unknown reasons. If your child is not developing as you expect, or if you believe that he or she may benefit from a combined approach, then pursuing additional therapies is an option to consider. Sharing your ideas and working cooperatively with the professionals who provide services for your child is a good way to explore the efficacy and practical application of other treatment approaches.

John Adlesich on healthcare industry trends: Democratic control in the Senate will also impact healthcare. For example, Washington state Senator Patty Murray will chair the Senate Committee on Health, Education, Labor, and Pensions. She has advocated for a more robust federal response on COVID-19. And Senator Ron Wyden, Oregon, leads the Finance Committee and has pushed for drug pricing reform and drug price negotiation. These appointments and nominations point to a strong emphasis on COVID-19 recovery and vaccine distribution and coordination. For example, Fauci remains as the Director of the National Institute of Allergies and Infectious Diseases, and there’s now a COVID-19 data director (Shahpar), indicating this administration will emphasize data and reporting. Also evident in these appointments is a Biden administration focus on health equity and healthcare disparities—particularly with Nunez-Smith as the first Equity Task Force Chair for COVID-19. John Adlesich currently works as administrator at Marquis Companies. His latest healthcare industry experience includes positions as executive director at Powerback Rehabilitation Lafayette (Genesis Healthcare) between Aug 2020 – Jan 2021, administrator at Mesa Vista of Boulder between Mar 2019 – Aug 2020, chief executive officer at Sedgwick County Memorial Hospital between Jul 2018 – Feb 2019, interim chief operating officer at Toiyabe Indian Health Project between Mar 2018 – Jun 2018.

John Adlesich believes that 2021 is an important year for the healthcare industry. There will be particular momentum for programs that have bipartisan support, including payment policies that move away from fee-for-service reimbursement and toward models that drive lower-cost and higher-quality outcomes. The overall movement to value will get a shot in the arm from two principal forces in 2021: 1) the Biden Administration’s commitment to build on the ACA’s legacy by doubling down on alternative payment models and mandatory payment changes and 2) the pandemic. When it comes to policy, the new Administration will not need convincing that value-based care improves quality and reduces costs. Ample research shows that since the move to value began, overall health spending as a percent of GDP has slowed, cutting more than $600 billion out of the budget trajectory that was predicted in 2010. Because these programs are net savers, expanding their reach will be an important and immediate objective that could be used to offset some of the COVID-19 relief spending. To that end, we are likely to see Biden’s HHS make fee-for-service less attractive and push at least some mandatory alternative payment models. In addition, the Administration is also likely to move beyond endless testing of models, making proven programs permanent, creating added incentives to enable scale, and leading the way for private payers to follow suit with value-based programs of their own.